Sanofi's pre-game show on Afrezza has MannKind followers chattering

Who doesn't like to watch a drug launch? It's pharma's version of a spectator sport, complete with cheerleaders--and booing opposition. And for Sanofi's ($SNY) upcoming rollout of Afrezza, the inhaled insulin developed by MannKind, the crowd is already assembling. Report